Brent A Morse Selected Research

CT-322

12/2012	Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture.
1/2011	Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts.
3/2010	Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brent A Morse Research Topics

Disease

4	Neoplasms (Cancer) 12/2012 - 03/2010
1	Vascular Remodeling 12/2012
1	Rhabdomyosarcoma 12/2012
1	Sarcoma (Soft Tissue Sarcoma) 12/2012
1	Ewing Sarcoma (Sarcoma, Ewing) 12/2012
1	Glioblastoma (Glioblastoma Multiforme) 03/2010
1	Carcinoma (Carcinomatosis) 03/2010

Drug/Important Bio-Agent (IBA)

3	CT-322IBA 12/2012 - 03/2010
1	Insulin-Like Growth Factor I (IGF-1)IBA 12/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2012
1	nimotuzumabIBA 01/2011
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 01/2011
1	Cetuximab (Erbitux)FDA Link 01/2011
1	Fibronectins (Fibronectin)IBA 01/2011
1	Panitumumab (Vectibix)FDA Link 01/2011
1	AntibodiesIBA 01/2011
1	Biological ProductsIBA 01/2011
1	Epidermal Growth Factor (EGF)IBA 01/2011
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2011
1	ErbB Receptors (EGF Receptor)IBA 01/2011
1	temsirolimus FDA Link 03/2010
1	Phosphotransferases (Kinase)IBA 03/2010
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 03/2010
1	Sorafenib (BAY 43-9006)FDA Link 03/2010
1	Sunitinib (Sutent)FDA Link 03/2010

Therapy/Procedure

3	Therapeutics 12/2012 - 01/2011